Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post‐platinum post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study
Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post‐platinum post‐pembrolizumab advanced urothelial carcinoma: A multicenter propensity score‐matched study
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now